摘要
Abstract
Objective To investigate the clinical efficacy of alisolizumab combined with statins in the treatment of elderly patients with coronary heart disease(CHD),and its impact on low-density lipoprotein cholesterol(LDL-C)level and prognosis.Methods In the random number table method,96 patients with CHD were divided into two groups:the control group(n=48)was treated with atorvastatin,while the study group(n=48)was treated with a combination of atorvastatin and aleximumab.Both groups were treated for 6 months.We compared the clinical efficacy,the level of blood lipids and prognosis between the two groups,and recorded the occurrence of drug adverse reactions.Results The total effective rate of the study group was higher than that of the control group(91.67%vs.75.00%,P<0.05).After treatment,the levels of triglycerides(TG),total cholesterol(TC),and LDL-C in the study group were all lower than those in the control group,while the level of high-density lipoprotein cholesterol(HDL-C)was higher than that in the control group(all P<0.05);the decreasing amplitude of TC and LDL-C,and the compliance rate of LDL-C in the study group after treatment were all higher than those in the control group(all P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Follow-up for 6 months,the total incidence of major adverse cardiovascular events in the study group was lower than that in the control group(P<0.05).Conclusion The combination of aliximumab and statins has an ideal therapeutic effect on CHD,which is beneficial for improving blood lipid indicators of elderly patients with CHD,effectively decreasing TC and LDL-C levels,improving the compliance rate of LDL-C,and reducing the risk of major adverse cardiovascular events.The clinical safety of combination therapy is relatively high.关键词
冠心病/阿利西尤单抗/阿托伐他汀/血脂/低密度脂蛋白胆固醇/预后Key words
coronary heart disease/aliximumab/atorvastatin/blood lipids/low-density lipoprotein cholesterol/prognosis分类
临床医学
